BUDGET IMPACT ANALYSIS OF REGORAFENIB FOR THE TREATMENT IN THIRD AND FOURTH LINES OF METASTASIC COLORECTAL CANCER IN SPAIN

Author(s)

González Flores E1, Vera García R2, Sabater Cabrera E3, Tirado Mercier E4, Granell Villalon M5
1Hospital Universitario Virgen de las Nieves, Granada, Spain, 2Complejo Hospitalario de Navarra, Pamplona, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 4Bayer Hispania S. L., Sant Joan Despí (Barcelona), Spain, 5Bayer Hispania S. L., Sant Joan Despí ( Barcelona ), Spain

OBJECTIVES:

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN64

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×